BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Low Cost Stocks to Buy According to Analysts. On September 8, Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) with a price target of $640.

The analyst noted that his rating is based on the strong results from Phase 3 trials for the company’s cat and birch allergy antibody cocktails. The results showed significant symptom reduction with key improvements seen in ocular itch, redness, and skin reaction, especially for cat allergy patients sensitized to FelD1.

Seigerman notes the clinical data address a large unmet medical need. However, he also points out uncertainty about commercial uptake due to generic antihistamines dominating allergy treatment. Despite this, he remains positive on Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN overall outlook.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that develops, manufactures, and sells medicines for serious diseases.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.